Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia

Haematologica

Volumn 100, Issue 3, 2015, Pages 295-

  Leoni, Veronica ^a   Biondi, Andrea ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BLINATUMOMAB; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; BISPECIFIC ANTIBODY; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER PROGNOSIS; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERANCE; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INCIDENCE; LEUKEMIA RELAPSE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY (TOPIC); MYELOABLATIVE CONDITIONING; PHILADELPHIA 1 CHROMOSOME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; ADULT; CHILD; CLINICAL TRIAL (TOPIC); GENETICS; HUMAN; MORTALITY; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION; SURVIVAL ANALYSIS;

ADULT; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; BENZAMIDES; CHILD; CLINICAL TRIALS AS TOPIC; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMATINIB MESYLATE; NEOPLASM, RESIDUAL; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 84924664857     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.124016     Document Type: Article

References (42)

1. Ottmann OG, Pfeifer H. Management of Philadelphia chromosomepositive acute lymphoblastic leukemia (Ph+ ALL). Hematology. 2009;371-379.
2. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Eng J Med. 2006;354:166-178.
3. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18(3):547-561.
4. Gleissner B, Gökbuget N, Bartram CR, et al. German Multicenter Trials of Adult Acute Lymphoblastic Leukemia Study Group. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 2002;99(5):1536-1543.
5. Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010;28(22):3644-3652.
6. Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leucemia. Blood. 2014;123(6):843-850.
7. Aricò M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Eng J Med. 2000;342:998-1006.
8. Aricò M, Schrappe M, Hunger SP, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol. 2010;28(31):4755-4761.
9. Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia confirms superiority of allogenic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009;113:4489-4496.
10. Marks DI, Wang T, Pérez WS, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010;116(3):366-374.
11. Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome– positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109(9):3676-3678.
12. Foà R, Vitale A, Vignetti M, et al. GIMEMA Acute Leukemia Working Party. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521-6528
13. Ottmann O, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoid leukemias. Blood. 2002;100:1965-1971.
14. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome- positive acute lymphoblastic leukemia with hyper-CVDA and imatinib mesylate. Blood. 2004;103:4396-4407.
15. Lee KH, Lee JH, Choi SJ, et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005;19:1509-1516.
16. Lee S, Kim YJ, Min CK, et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2005;105:3449-3457.
17. Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24:460-466.
18. Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2006;108:1469–1477.
19. Delannoy A, Delabesse E, Lheritier V, et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia. 2006;20:1526-1532.
20. De Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2007;109:1408-1413.
21. Ribera JM, Oriol A, Gonzales M, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philandelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Heamatologica. 2010;95(1):87-95.
22. Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116 (12):2070-2077.
23. Schultz KR, Carroll A, Heerema NA, et al. Children’s Oncology Group. Long-term follow-up of imatinib in paediatric Philadelphia chromosome- positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031. Leukemia. 2014;28(7):1467-1471.
24. Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosomepositive acute lymphoblastic leukaemia (EsPhALL): a randomised, open label, intergroup study. Lancet Oncol. 2012;13(9):936-945.
25. Fielding AK. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2010;116(18):3409-3417.
26. Rousselot P, Coudé MM, Huguet F, et al. Dasatinib (Sprycel®) and low intensity chemotherapy for first-Line treatment in patients with de novo philadelphia positive ALL aged 55 and over: final results of the EWALL-Ph-01 study. Blood. ASH Annual Meeting Abstracts. 2012;120: Abstract 666.
27. Ottman OG, Pfeifer H, Cayuela JM, et al. Nilotinib (Tasigna®) and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia chromosome/BCR-ABL1 positive acute lymphoblastic leukemia (ALL): A trial of the European Working Group for Adult ALL (EWALL-PH-02). ASH Annual Meeting Abstracts. 2014; Abstract 798.
28. Jabbour E, Kantarjian HM, Thomas DA, et al. Phase II study of combination of hypercvad with ponatinib in front line therapy of patients (pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL). ASH Annual Meeting Abstracts. 2014; Abstract 2289.
29. Lee S, Kim DW, Cho B, et al. Risk factors for adults with Philadelphiachromosome- positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol. 2003;120(1):145-153.
30. Ottmann OG, Wassmann B, Pfeifer H, et al. GMALL Study Group. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer. 2007;109(10):2068-2076.
31. Yanada M, Sugiura I, Takeuchi J, et al. Japan Adult Leukemia Study Group. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol. 2008;143(4):503-510.
32. Pfeifer H, Wassmann B, Bethge W, et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukaemia. Leucemia. 2013;27:1254-1262.
33. Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in346 patients. Blood. 1995;85:2632-2638.
34. Stirewalt DL, Guthrie KA, Beppu L, et al. Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. Biol Blood Marrow Transplant. 2003;9:206-212.
35. Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome–positive leucemia. Blood. 2007;109:2791-2793.
36. Anderlini P, Sheth S, Hicks K, Ippoliti C, Giralt S, Champlin RE. Imatinib mesylate administration in the first 100 days after stem cell transplantation. Biol Blood Marrow Transplant. 2004;10:883-884.
37. Wassmann B, Pfeifer H, Stadler M, et al. Early molecular response to post-transplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2005;106(2):458-463.
38. Burke MJ, Trotz B, Luo X, et al. Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. Bone Marrow Transplant. 2009;43:107-113.
39. Bachanova V, Marks DI, Zhang MJ, et al. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia. 2014;28(3):658-665.
40. Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graftversus- host disease with fibrotic features. Blood. 2009;114(3):709-718.
41. Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cellengaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493-2498.
42. Schlegel P, Lang P, Zugmaier G, et al. Pediatric post-transplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica. 2014;99(7):1212-1219.